Driving innovation in obesity and endocrinology clinical development
IQVIA Laboratories offers the scientific leadership and global infrastructure to help you move faster. With over 150 therapeutics currently in clinical phases, speed and precision are critical. Because we understand and have vast experience in these complex disease states, we offer operational efficiency, regulatory expertise, and advanced instrumentation that can generate high-quality data faster, so you can be first to market with effective therapies.

Advance your obesity and endocrinology drug development with the power of IQVIA Laboratories
IQVIA Laboratories is driving innovation in obesity drug development. Our expertise spans from complex biomarker quantification to high-throughput assay validation, delivering accurate, reproducible data that drives confident decision-making.
We understand that therapies targeting obesity, Type 2 Diabetes (T2D) and broader endocrine disorders often present unique bioanalytical challenges due to their complex molecular structures and mechanisms of action. That’s why we apply advanced pharmacokinetic (PK) and pharmacodynamic (PD) profiling, along with robust ADME (absorption, distribution, metabolism, excretion) strategies.
With a rigorous, science-driven approach, IQVIA Laboratories ensures precision, reproducibility and speed across every stage of your drug development program—empowering you to bring life-changing therapies to patients faster.
The Future of Obesity
Almost 2/3 of adults are estimated to be overweight or obese by 2050, at 3.8 billion*
Obesity rising in children and adolescents: 121% forecast increase for the next 30 years*
‘Source: The Lancet (2025): Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Copyright © 2025 IQVIA. All rights reserved.
IQVIA Laboratories’ Obesity Portfolio
Obesity-specific trials
Patients supported
biosamples managed
What makes IQVIA Laboratories a leader in obesity and endocrinology drug development?
Our scientific expertise and laboratory services are designed to support the full lifecycle of obesity and endocrinology drug development.
- Therapeutic and analytical expertise in key endocrine, metabolic indications, and lipid analysis
- Clinical laboratory assessments, including standard safety, biomarkers, PK and immunogenicity
- Assay Validation: Ensure accuracy and compliance with customized assay validation for reliable bioanalytical results.
- ADME Metabolism Exploration: Gain deep insights into drug absorption, distribution, metabolism, and excretion with expert ADME profiling.
- Regulated LC-MS Bioanalysis: Achieve high-sensitivity, regulatory-compliant LC-MS bioanalysis.
- Soluble Protein Testing: Accurately measure protein solubility and binding interactions to support pharmacokinetic evaluations.
- Translational Biomarker Solutions: Bridge preclinical and clinical research with biomarker strategies that drive precision medicine.
Our therapeutic modalities
- Large and small molecules
- GLP-1, GIP, glucagon agonists
- MC4R
- Fixed combination therapies
- Antibodies and antibody-drug conjugates (ADCs)
- Proteins
- Peptides
- Oligonucleotides
- ASO
- siRNA

Our expert-led methodologies
IQVIA Laboratories provides both regulated and non-regulated bioanalytical services using advanced liquid chromatography-mass spectrometry (LC-MS) and high-resolution mass spectrometry (HRMS) platforms. These services are essential for supporting ADME studies—studying the absorption, distribution, metabolism and excretion of a drug—from phase I safety studies through dosing studies in phase II and III studies.
What are the capabilities needed to bring an obesity drug to market?
Research and discovery bioanalysis
- In silico and in vitro lead optimization and candidate screening
- Exploratory ADME profiling
- Biomarker discovery and metabolite identification
- High-throughput soluble protein immunoassays for broad biomarker discovery
- Rapid method development and feasibility studies
- These services help accelerate timelines and reduce risk in early development.
GLP-compliant bioanalysis
If you're looking for GLP-compliant assays for regulatory submissions, our regulated services are designed to meet the highest standards. We provide:
- Validated LC-MS/HRMS methods for small molecules and biologics
- Full compliance with FDA, EMA, and ICH guidelines
- Support for preclinical toxicology, first-in-human (FIH) studies, and clinical PK/PD assessments including multiplexed immunoassays
- High-quality, reproducible data for regulatory filings
- In vivo drug-drug interaction (DDI) study support. Click to see our full list of non-proprietary methods.
IQVIA Laboratories offers a full spectrum of lab services, from discovery to commercialization
*Biosciences’ services
Frequently Asked Questions
Can IQVIA Laboratories develop and validate custom bioanalytical assays for my program?
Yes. IQVIA Laboratories offers full-service assay development and validation tailored to your molecule and study needs.
Can IQVIA Laboratories support both small and large molecule drug development?
Yes. Our LC-MS and HRMS platforms are optimized for a wide range of therapeutic modalities, including peptides, proteins, and complex biologics.
What lab services does IQVIA Laboratories offer for obesity and endocrinology drug development?
We provide LC-MS-based bioanalysis, biomarker validation, PK/PD profiling, and assay development tailored to obesity and metabolic therapies.
Can IQVIA Laboratories support endocrine clinical trials?
Yes. We support trials for thyroid, adrenal and pituitary disorders, as well as diabetes and hormonal therapies.
How does IQVIA Laboratories ensure data quality and regulatory compliance?
Our labs follow GLP/GCP standards and are equipped for FDA, EMA, and ICH-compliant submissions.
Ready to accelerate your obesity or endocrinology program?
Contact IQVIA Laboratories today to learn how our expertise and services can support your regulated and non-regulated bioanalysis needs.
Related Insights

Mass Matters: Expertise in Addressing Drug Bioanalysis for T2D and Obesity with LC-MS
